SCHEMBL23436

SCHEMBL23436

CCOC(=O)[C@H](Cc1cccc(OC)c1)N=C(c1ccccc1)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 2/20 0.45
ALDH1A1 P00352 3/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
CTBP2 P56545 1/20 0.44
MMP13 P45452 1/20 0.44
CTSD P07339 1/20 0.44
MRGPRX4 Q96LA9 1/20 0.43
KDM4E B2RXH2 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
GPR52 Q9Y2T5 1/20 0.43
HIF1A Q16665 1/20 0.43
LMNA P02545 1/20 0.43
HPGD P15428 1/20 0.43
PARP1 P09874 1/20 0.43
MAPT P10636 1/20 0.42
MTNR1A P48039 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18833 1.00 TAAR1 (0.45) TAAR1ALDH1A1L3MBTL1TSHRMAPK1
SCHEMBL30831587 1.00 TAAR1 (0.45) TAAR1ALDH1A1L3MBTL1TSHRMAPK1
SCHEMBL395095 0.90 MRGPRX4 (0.42) L3MBTL1TSHRMAPK1TDP1MRGPRX4
SCHEMBL26995231 0.88 TRPM8 (0.45) L3MBTL1TSHRMAPK1TDP1MRGPRX4
SCHEMBL31506282 0.88 TRPM8 (0.45) L3MBTL1TSHRMAPK1TDP1MRGPRX4
SCHEMBL26985738 0.88 TAAR1 (0.49) TAAR1CTBP2MMP13CTSDMRGPRX4
SCHEMBL27131765 0.88 TAAR1 (0.49) TAAR1CTBP2MMP13CTSDMRGPRX4
SCHEMBL26995244 0.86 RAB9A (0.47) ALDH1A1L3MBTL1MAPK1MRGPRX4KDM4E
SCHEMBL30831549 0.86 RAB9A (0.47) ALDH1A1L3MBTL1MAPK1MRGPRX4KDM4E
SCHEMBL3819101 0.84 RAB9A (0.47) ALDH1A1MAPK1MEN1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001846-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS SERVIER LAB (FR) 2026-01-01 US disclosed
EP-2609081-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES Amgen Inc. (US) 2013-07-03 EP disclosed
US-8431563-B2 Compounds that interact with glucokinase regulatory protein for the treatment of diabetes AMGEN INC. (US) 2013-04-30 US disclosed
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-09-06 US disclosed
WO-2012027261-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001846-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS BCL2, BCL2A1, BAX TAAR1 4007/4885ALDH1A1 1848/4885L3MBTL1 1235/4885
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES GCKR, GCK, SLC5A2 TAAR1 4778/4885ALDH1A1 3293/4885L3MBTL1 4623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.